/Lists

Biotech Late Stage Investors & VC Firms

360 firms in this list, with a median first check of $1M. 82 of them lead rounds. Generated from verified public data and updated continuously.

Ridgeback Capital
New YorkSeed–Late Stage
2 people
Panacea Venture
SingaporeSeed–Late Stage
22 people
Catalyst Investments, L.P.
Tel AvivGrowth–Late Stage$1.5M – $5M
29 people
Cenova Capital
ShanghaiSeries B–Late Stage
22 people
K2 HealthVentures
BostonGrowth–Late Stage
22 people
UKSE
SheffieldSeries A–Late Stage
35 people
Dentsu Ventures
TokyoSeed–Late Stage
12 people
TCG Crossover
Palo AltoSeed–Late Stage
29 people
Mitsui Global Investment
Menlo ParkPre-Seed–Late Stage$500K – $10M
12 people
Sutter Hill Ventures
Palo AltoSeed–Late Stage$100K – $5M
14 people
+ND Capital
WoodsideSeed–Late Stage$540K – $5.4M
17 people
Industrial Technology Investment Corporation
TaipeiPre-Seed–Late Stage
15 people
E2MC Ventures
OrlandoPre-Seed–Late Stage$250K – $2M
16 people
Ajax Health
Menlo ParkSeed–Late Stage
29 people
Revelation Partners
SausalitoGrowth–Late Stage$5M – $50M
15 people
LYFE Capital
Menlo ParkSeed–Late Stage
22 people
Northstar Ventures
Newcastle upon TynePre-Seed–Seed$38.1K – $1.3M
17 people
Pivotal Life Sciences
San FranciscoPre-Seed–Late Stage
14 people
Pontifax Venture Capital
HerzeliyaSeed–Late Stage
7 people
Tullis Health Investors
Palm Beach GardensSeries A–Late Stage$500K – $10M
17 people
Kilonova Capital
San FranciscoGrowth–Late Stage$25M – $150M
25 people
TrueLight Capital
SingaporeSeed–Late Stage
28 people
Tal Ventures
Tel AvivPre-Seed–Late Stage
8 people
Miyako Capital
KyotoSeed–Late Stage
14 people

Related lists

Data sourced from public filings and firms' own websites — see our methodology.